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Research or Clinical Tool?*Nicolas M. Van Mieghem, MD, PHD, Lennart van Gils, MDT ranscatheter MitraClip (Abbott Vascular,Santa Clara, California) implantation hasemerged as the single catheter-based tech-
nique for mitral valve repair with global adoption.
Worldwide, an estimated 25,000 patients have been
treated with the MitraClip so far. Typically, the
incidence of major stroke after surgical mitral valve
repair or replacement is similar to what is seen after
surgical aortic valve replacement, and varies be-
tween 1% and 5% (1–3). In the only randomized trial
comparing MitraClip with mitral valve repair/
replacement, major stroke rate at 30 days was 1%
after MitraClip and 2% after mitral valve surgery (4).
The EVEREST (Endovascular Valve Edge-to-Edge
Repair Study) 2 predominantly enrolled patients with
degenerative mitral valve disease (4). In the larger
European MitraClip registries, patients had more
functional mitral regurgitation (MR). The clinically
major stroke rate after clipping appeared to be negli-
gible and <1%: 0.7% in 560 patients in the ACCESS
EU (ACCESS-Europe A Two-Phase Observational Study
of the MitraClip System in Europe) trial, and 0% in
1,064 patients in the German TRAMI (Transcatheter
Mitral Valve Interventions) Registry (5,6).
Important lessons were learned after a decade of
controversy about stroke rates in patients undergoing
surgical or catheter-based aortic valve replacement.
The randomized PARTNER (Placement of Aortic
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ment (TAVR)was associatedwith a higher neurological
event rate compared with surgical aortic valve
replacement; yet, the randomized U.S. CoreValve
high-risk study refuted these ﬁndings (7,8). Interest-
ingly, the involvement of competent authorities like
the U.S. Food and Drug Administration, efforts by the
Valve Academic Research Consortium to determine
uniformity in endpoint deﬁnitions and trial design,
and the advent of embolic protection devices have
scrutinized research on neurological events in the ﬁeld
(9). Neurology experts are now involved in most
important TAVR trials and assess all enrolled patients
undergoing valve replacement before and after the
procedure. This scrutiny has revealed more (subtle)
neurological changes in signiﬁcantly more patients.
Indeed, new neurological events were detected in 15%
of patients in the control arm of the randomized
DEFLECT III (A Prospective, Randomized Evalua-
tion of the TriGuard HDH Embolic Deﬂection Device
During TAVI) trial and in 17% of patients undergoing
surgical aortic valve replacement in the DeNOVO
(Determining Neurologic Outcomes from Valve Oper-
ations) prospective cohort study (10,11). Diffusion-
weighted magnetic resonance imaging (MRI) studies
and histopathology studies have revealed signs of
cerebral embolization in over 80% of patients under-
going TAVR (12–14).SEE PAGE 171Deﬂecting and ﬁlter-based embolic protection de-
vices (EPDs) are being intensely studied in the ﬁeld of
TAVR, and not surprisingly, interest for EPD also
emerges in the MitraClip space (15). In this issue of
JACC: Cardiovascular Interventions, Frerker et al. (16)
study the use of ﬁlter-based embolic protection
in patients undergoing MitraClip implantation.
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181The Sentinel EPD (Claret Medical Inc., Santa Rosa,
California) provides ﬁlter protection for 3 of 4 arterial
contributories to the brain. The ﬁlters can be retrieved
and microscopically analyzed. Fourteen patients with
severe MR were included in the analysis. Most pa-
tients had functional MR and concomitant permanent
atrial ﬁbrillation. Debris was detected in all patients.
Acute thrombus and foreign body material was most
common. The presence of acute thrombus is remark-
able, especially since optimal per-procedural anti-
coagulation with heparin was achieved (mean
activated clotting time 289  48 s). This raises the
question about the etiology of this acute clot forma-
tion: device manipulations in the left side of the
heart but also the use of the ﬁlters themselves may
be pro-thrombogenic. Furthermore, procedure times
exceeding 90 min may result in transient suboptimal
anticoagulation and, thus, promote acute thrombus
formation. In fact, MitraClip procedure/device time
has previously been associated with more new brain
lesions by MRI (17). Conversely, the presence of orga-
nizing thrombus in the ﬁlters may be associated with
the high prevalence of atrial ﬁbrillation that hypo-
thetically may have accounted for the organized
thrombus surrounding the mitral valve apparatus.
The authors describe the foreign body material
as nonpolarizable basophilic material consistent
with hydrogel, most probably from the hydrophilic
coating of the transseptal sheath, guide delivery
catheter, or the clip delivery system and thus
inherent to the procedure. In more than one-half of
the patients, mitral valve and atrial tissue was
found. The authors do not discuss the effect of the
number of attempts to grasp both mitral leaﬂets to
eventually close and deploy the MitraClip. One can
only wonder whether more attempts could dislodge
more tissue. Furthermore, would there be a differ-
ence between functional and degenerative MR, with
the latter displaying an excess of tissue? The ﬁnding
that the use of more clips seemed to generate larger
debris is intriguing.
In comparison to what typically is captured after
TAVR, debris seemed smaller with MitraClip: 295 mm(interquartile range: 104 to 509 mm) versus 1 mm
(interquartile range: 0.6 to 1.5 mm) (14). Smaller
particle size may reﬂect the preponderance of func-
tional MR in this study with structurally normal
mitral valve leaﬂets. Similarly, this may explain
why no calcium particles were captured. This
contrasts with the yield after TAVR, with tissue
debris in two-thirds of all patients including amor-
phous calcium.
The current data are complementary to the recent
brain MRI study by Blazek et al. (17), in which a
median of 3 new brain lesions were found in 85% of
patients after MitraClip.
Given the (very) low clinical stroke rates after
MitraClip, purists may claim that EPDs are useless in
this setting. Others may argue that even subclinical
brain infarcts may not be harmless and may increase
the risk for dementia and neurocognitive deteriora-
tion in the long run (18). Future research efforts may
focus on: 1) the difference in cerebral embolization
between functional and degenerative MR; 2) the
effect of EPD on new brain lesions by MRI; 3) cerebral
embolization burden with transcatheter mitral valve
implantation, which intuitively seems more trau-
matic than MitraClip and may thus dislodge more
tissue debris; and maybe most importantly, 4) the
effect of new brain lesions after structural heart
interventions on immediate and late neurocognitive
performance.
In aggregate, cerebral embolization seems ubiqui-
tous with structural left-sided heart interventions.
The study by Frerker et al. (16) provides comple-
mentary histopathological evidence to prior brain
imaging data. Only the future can tell whether ﬁlter-
based cerebral embolic protection is merely an inter-
esting research tool or an essential clinical accessory
for superior procedural (brain) safety.
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